IP Library Granted Patent US 9,833,441
Granted Patent B2
US 9,833,441 · App. 15/073,139 · Granted Dec 5, 2017

Compositions and methods for the treatment of presbyopia

Inventors: Gerald Horn (Deerfield, IL); Lee Nordan (Dana Point, CA)
Assignee: Presbyopia Therapies LLC
A61K31/439A61K9/0048A61K9/08A61K31/165A61K31/4164A61K31/4409A61K31/498A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,441
App. No.
15/073,139
Granted
Dec 5, 2017
Kind
B2
Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cycloplegic agent. The compositions optionally contain a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.

Claims (12)

1. An ophthalmological composition for the treatment of presbyopia comprising an active agent consisting of aceclidine and a cycloplegic agent.

2. The ophthalmological composition according to claim 1 , wherein aceclidine is at a concentration from about 0.25% to about 2.0% w/v, wherein w/v denotes weight by volume.

3. The ophthalmological composition according to claim 2 , wherein the cycloplegic agent is tropicamide.

4. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

5. A method of treating irregular astigmatism, keratoconic ectasia, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

6. An ophthalmological composition for the treatment of presbyopia comprising an active agent consisting of aceclidine and about 0.004% to about 0.08% w/v of a cycloplegic agent, wherein w/v denotes weight by volume.

7. The ophthalmological composition according to claim 6 , wherein the cycloplegic agent is at a concentration from about 0.004% to about 0.049% w/v.

8. The ophthalmological composition according to claim 7 , wherein the cycloplegic agent is at a concentration from about 0.004% to about 0.025% w/v.

9. The ophthalmological composition according to claim 6 , wherein aceclidine is at a concentration from about 0.25% to about 2.0% w/v, wherein w/v denotes weight by volume.

10. The ophthalmological composition according to claim 6 , wherein the cycloplegic agent is tropicamide.

11. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 6 .

12. A method of treating irregular astigmatism, keratoconic ectasia, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 6 .

Assignments (4)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
CHANGE OF NAME Recorded Dec 15, 2022
From: PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 062138/0206 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: HORN, GERALD; NORDAN, LEE
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052849/0632 →
Continuity (8)
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 14223639 · Mar 24, 2014
Provisional Application 61938438 · Feb 11, 2014
Provisional Application 61917620 · Dec 18, 2013
Provisional Application 61904510 · Nov 15, 2013
Provisional Application 61882998 · Sep 26, 2013
Provisional Application 61871215 · Aug 28, 2013
Related Publication 20160193194A1 · Jul 7, 2016